Acesso livre
Acesso livre

Farmácia/Notícias da Indústria

Coleção Cochrane | Atingindo a atenção sustentável à saúde por meio da retirada de medicamentos desnecessários.

9 Ago, 2022 | 17:27h

Achieving sustainable healthcare through deprescribing of unnecessary medications: making sense of the evidence – Cochrane Library

 

Avaliação crítica da evidência atual | Recomendações de dosagem de antibióticos na terapia de substituição renal contínua pediátrica.

9 Ago, 2022 | 16:37h

Antimicrobial Dosing Recommendations in Pediatric Continuous Renal Replacement Therapy: A Critical Appraisal of Current Evidence – Frontiers in Pediatrics

 

Estudo de caso-controle | Uso ambulatorial de macrolídeo oral está associado com risco aumentado de perda de audição neurossensorial em crianças, adolescentes e jovens adultos.

5 Ago, 2022 | 17:39h

Association of Outpatient Oral Macrolide Use With Sensorineural Hearing Loss in Children, Adolescents, and Young Adults – JAMA Otolaryngology-Head & Neck Surgery (link para o resumo – $ para o texto completo)

Comentário: Kids’ Hearing Loss Associated With Common Antibiotics — Children and teens with sensorineural hearing loss more often macrolide users – MedPage Today (necessário cadastro gratuito)

 

Estudo de coorte | Risco de overdose de opioide é aumentado pelo uso concomitante de oxicodona e inibidores seletivos de recaptação de serotonina que inibem o metabolismo da oxicodona.

5 Ago, 2022 | 17:37h

Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors – JAMA Network Open

Comentário do autor: Taking certain opioids while on commonly prescribed antidepressants may increase the risk of overdose – The Conversation

 

Comentário no Twitter

 

M-A | Eficácia da doxiciclina para pneumonia adquirida na comunidade leve a moderada em adultos.

5 Ago, 2022 | 17:34h

Efficacy of Doxycycline for Mild-to-moderate Community-acquired Pneumonia in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials – Clinical Infectious Diseases (link para o resumo – $ para o texto completo)

 

Comentário no Twitter

 

Estudo randomizado | Comparação da mudança para dose a cada 6 semanas de natalizumabe vs. continuar a dose a cada 4 semanas em pacientes com esclerose múltipla recorrente-remitente.

5 Ago, 2022 | 17:05h

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial – The Lancet Neurology (link para o resumo – $ para o texto completo)

Comentário: Less Frequent Dosing With MS Drug Safe With No Loss of Efficacy – Medscape (necessário cadastro gratuito)

 

Estudo RECOVERY | Baricitinibe em pacientes hospitalizados com COVID-19.

5 Ago, 2022 | 16:50h

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis – The Lancet

Comentário convidado: Baricitinib in COVID-19: a coming-of-age from artificial intelligence to reducing mortality – The Lancet

Conteúdos relacionados:

Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial – medRxiv

Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial – The Lancet Respiratory Medicine

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis – medRxiv

WHO recommends two new drugs to treat COVID-19 – World Health Organization

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial – The Lancet Respiratory Medicine

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 – New England Journal of Medicine

 

Comentário no Twitter

Sob licença de Creative Commons Attribution (CC BY 4.0)

 

M-A | Resposta à monoterapia farmacológica aguda para transtornos depressivos maiores em estudos randomizados e placebo-controlados.

5 Ago, 2022 | 16:48h

Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials submitted to the US Food and Drug Administration: individual participant data analysis – The BMJ

 

Resumo de evidência | Retirada de medicamentos em idosos convivendo com multimorbidade e polifarmácia.

5 Ago, 2022 | 16:38h

Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis – Health Technology Assessment

Conteúdos relacionados:

Antihypertensive Deprescribing in Older Adults: a Practical Guide – Current Hypertension Reports

How-to guide for medication reviews in older adults with cancer: A Young International Society of Geriatric Oncology and Nursing & Allied Health Interest Group initiative – Journal of Geriatric Oncology

Deprescribing in Palliative Cancer Care – Life

Less is More: Deprescribing Medications in Older Adults with Kidney Disease: A Review – Kidney360

Process evaluation of implementation strategies to reduce potentially inappropriate medication prescribing in older population: A scoping review – Research in Social and Administrative Pharmacy

AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review – Gastroenterology

Development of a Metric to Detect and Decrease Low-Value Prescribing in Older Adults – JAMA Network Open

The MedSafer Study—Electronic Decision Support for Deprescribing in Hospitalized Older Adults: A Cluster Randomized Clinical Trial – JAMA Internal Medicine

Quantifying Anticholinergic Burden and Sedative Load in Older Adults with Polypharmacy: A Systematic Review of Risk Scales and Models – Drugs & Aging

Deprescribing in palliative patients with cancer: a concise review of tools and guidelines – Supportive Care in Cancer

Prescribing practices, patterns, and potential harms in patients receiving palliative care: A systematic scoping review – Exploratory Research in Clinical and Social Pharmacy

A narrative review of evidence to guide deprescribing among older adults – Journal of General and Family Medicine

Polypharmacy, inappropriate prescribing, and deprescribing in older people: through a sex and gender lens – The Lancet Health Longevity

Polypharmacy Management in Older Patients – Mayo Clinic Proceedings

Psychopharmacological Treatment in Older People: Avoiding Drug Interactions and Polypharmacy – Deutsches Ärzteblatt international

Eliminating Medication Overload: A National Action Plan – Lown Institute

International Group for Reducing Inappropriate Medication Use & Polypharmacy (IGRIMUP): Position Statement and 10 Recommendations for Action – Drugs & Aging

Common ED Medication Errors: Polypharmacy – emDocs

Current and future perspectives on the management of polypharmacy – BMC Family Practice

Routine deprescribing of chronic medications to combat polypharmacy – Therapeutic Advances in Drug Safety

Polypharmacy—an Upward Trend with Unpredictable Effects – Deutsches Ärzteblatt international

Clinical Consequences of Polypharmacy in Elderly – Expert Opinion on Drug Safety

 

Diretriz | Terapia de deprivação androgênica: eventos adversos e estratégias de tratamento.

5 Ago, 2022 | 16:32h

UPDATE – Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies (Full-text) – Canadian Urological Association Journal

 

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.